Elizabeth Stoner Sells 3,399 Shares of Momenta Pharmaceuticals, Inc. (MNTA) Stock


Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Director Elizabeth Stoner sold 3,399 shares of the stock in a transaction on Wednesday, March 21st. The stock was sold at an average price of $19.00, for a total value of $64,581.00. Following the completion of the sale, the director now owns 21,176 shares in the company, valued at approximately $402,344. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.


Elizabeth Stoner also recently made the following trade(s):

How to Become a New Pot Stock Millionaire

On Tuesday, April 10th, Elizabeth Stoner sold 3,399 shares of Momenta Pharmaceuticals stock. The stock was sold at an average price of $19.00, for a total value of $64,581.00. On Tuesday, January 30th, Elizabeth Stoner sold 16,264 shares of Momenta Pharmaceuticals stock. The stock was sold at an average price of $18.00, for a total value of $292,752.00.


Shares of Momenta Pharmaceuticals stock traded up $0.20 during trading on Thursday, hitting $19.70. 934,798 shares of the stock traded hands, compared to its average volume of 901,872. The firm has a market cap of $1,448.78, a P/E ratio of -16.42 and a beta of 1.64. Momenta Pharmaceuticals, Inc. has a 52-week low of $11.85 and a 52-week high of $20.25.

Momenta Pharmaceuticals (NASDAQ:MNTA) last announced its quarterly earnings results on Wednesday, February 21st. The biotechnology company reported $0.18 EPS for the quarter, beating the consensus estimate of $0.06 by $0.12. The firm had revenue of $64.60 million for the quarter, compared to analyst estimates of $66.59 million. Momenta Pharmaceuticals had a negative return on equity of 23.62% and a negative net margin of 63.43%. The business’s revenue for the quarter was up 88.9% on a year-over-year basis. During the same quarter last year, the firm posted $0.60 earnings per share. research analysts forecast that Momenta Pharmaceuticals, Inc. will post -1.27 earnings per share for the current year.


A number of institutional investors and hedge funds have recently bought and sold shares of MNTA. Tocqueville Asset Management L.P. grew its stake in Momenta Pharmaceuticals by 243.6% in the fourth quarter. Tocqueville Asset Management L.P. now owns 963,784 shares of the biotechnology company’s stock valued at $13,445,000 after purchasing an additional 683,296 shares during the last quarter. Renaissance Technologies LLC grew its stake in Momenta Pharmaceuticals by 9.3% in the fourth quarter. Renaissance Technologies LLC now owns 1,583,000 shares of the biotechnology company’s stock valued at $22,083,000 after purchasing an additional 134,500 shares during the last quarter. Sectoral Asset Management Inc grew its stake in Momenta Pharmaceuticals by 34.3% in the fourth quarter. Sectoral Asset Management Inc now owns 500,298 shares of the biotechnology company’s stock valued at $6,979,000 after purchasing an additional 127,799 shares during the last quarter. Arizona State Retirement System grew its stake in Momenta Pharmaceuticals by 224.8% in the fourth quarter. Arizona State Retirement System now owns 128,388 shares of the biotechnology company’s stock valued at $1,791,000 after purchasing an additional 88,854 shares during the last quarter. Finally, BlackRock Inc. grew its stake in Momenta Pharmaceuticals by 0.8% in the fourth quarter. BlackRock Inc. now owns 10,473,316 shares of the biotechnology company’s stock valued at $146,105,000 after purchasing an additional 82,691 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.


MNTA has been the topic of several research reports. BidaskClub lowered Momenta Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, February 22nd. Stifel Nicolaus restated a “hold” rating and set a $18.00 price target on shares of Momenta Pharmaceuticals in a research note on Tuesday, January 30th. ValuEngine upgraded Momenta Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, April 3rd. Finally, Zacks Investment Research upgraded Momenta Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, January 2nd. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and three have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $15.33.


COPYRIGHT VIOLATION NOTICE: This report was published by Ticker Report and is the sole property of of Ticker Report. If you are viewing this report on another website, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The original version of this report can be viewed at www.tickerreport.com/banking-finance/3352090/elizabeth-stoner-sells-3399-shares-of-momenta-pharmaceuticals-inc-mnta-stock.html.

About Momenta Pharmaceuticals

Momenta Pharmaceuticals, Inc, a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for autoimmune diseases in the United States. The company's complex generics programs include Enoxaparin sodium injection, a generic version of Lovenox that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing-remitting multiple sclerosis; and GLATOPA, a generic product candidate for three-times-weekly COPAXONE.

Insider Buying and Selling by Quarter for Momenta Pharmaceuticals (NASDAQ:<b><a href=MNTA)' title='Insider Buying and Selling by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)' />

Leave a Reply

Your email address will not be published. Required fields are marked *